Literature DB >> 30553716

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Julia K Rotow1, Gavitt A Woodard2, Anatoly Urisman3, Caroline E McCoach1, Trever G Bivona1, Brett M Elicker4, David M Jablons2, Collin M Blakely5.   

Abstract

Entities:  

Keywords:  Non-small cell lung cancer; Perioperative; Stage III; Targeted therapy; Tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2018        PMID： 30553716     DOI： 10.1016/j.cllc.2018.11.003

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

1.  Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

Authors:  Marissa S Mattar; Jason Chang; Ryma Benayed; Darragh Halpenny; Astin Powers; David E Kleiner; Alexander Drilon; Mark G Kris
Journal:  Clin Lung Cancer       Date:  2019-10-13       Impact factor: 4.785

Review 2.  Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.

Authors:  Caiwen Huang; Qihua Zou; Hui Liu; Bo Qiu; Qiwen Li; Yongbin Lin; Ying Liang
Journal:  Curr Treat Options Oncol       Date:  2020-04-18

3.  Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report.

Authors:  Meng Fu; Chun-Mei Feng; Da-Qing Xia; Zi-Mei Ji; Huai-Ling Xia; Na-Na Hu; Zai-Jun Leng; Wang Xie; Yuan Fang; Le-Jie Cao; Jun-Qiang Zhang
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

4.  Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.

Authors:  Yu Zhang; Hao Zhang; Hanqing Wang; Jingtong Zeng; Bo Zhang; Ning Zhou; Lingling Zu; Zuoqing Song; Changli Wang; Song Xu
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.